2017 - PRESS RELEASES
Myonexus Therapeutics Secures $ 2,5 Million Seed Financing to Clinically Advance Limb-Girdle Muscular Dystrophy (LGMD) Gene Theraphies - December 13th 2017
Clinical Trials Bring Hope to Kids with Spinal Muscular Atrophy - November 21th 2017
FDA Clears IND Application for Micro-dystrophin Gene Therapy Program to Treat Duchenne - November 8th 2017
Sarepta & Nationwide Announce FDA Clearance of IND for Micro-Dystrophin Gene Therapy Program for the Treatment of Duchenne – November 6th 2017
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy – November 2nd 2017
Gene Therapy Continues to Show Promise for Limb-Girdle Muscular Dystrophy – June 13th 2017
Myonexus Therapeutics, Inc. Launches to Develop Pioneering, Clinical-Stage Gene Therapies Targeting Limb-Girdle Muscular Dystrophies - June 7th 2017
Myonexus Launches Development of Gene Therapies Targeting Limb-Girdle MD - June 8th 2017
Promising Preclinical results for LGMD gene therapy – Muscular Dystrophy UK - February 8th 2017
- Hits: 1055